# Guaifenesin

Guaifenesin, also known as glyceryl guaiacolate, is an expectorant medication taken by mouth and marketed as an aid to eliminate sputum from the respiratory tract. Chemically, it is an ether of guaiacol and glycerine. It may be used in combination with other medications. A 2014 study found that guaifenesin does not affect sputum volume in upper respiratory infections (the upper respiratory system includes most breathing parts above the lungs).
Side effects may include dizziness, sleepiness, skin rash, and nausea. While it has not been properly studied in pregnancy, it appears to be safe. It has been alleged to work in 2023 by making airway secretions more liquid, even as it has been demonstrated not to work.
Guaifenesin has been used medically since at least 1933. It is available as a generic medication and over-the-counter (OTC). In 2022, it was the 295th most commonly prescribed medication in the United States, with more than 400,000 prescriptions. In 2022, the combination dextromethorphan/guaifenesin was the 290th most commonly prescribed medication in the United States, with more than 400,000 prescriptions.

## Medical uses

Guaifenesin is used to try to help with coughing up thick mucus. It is sometimes combined with the antitussive (cough suppressant) dextromethorphan, such as in Mucinex DM or Robitussin DM. It is also combined with ephedrine in Primatene and Bronkaid tablets for symptomatic relief of asthma. Guaifenesin is combined with phenylephrine and paracetamol in certain Lemsip formulations.
A Cochrane review identified three clinical trials assessing guaifenesin for the treatment of acute cough, with one finding significant benefit and the other two trials finding that it was not effective.

## Side effects

Although generally well-tolerated, side effects of guaifenesin may include an allergic reaction (rare), nausea, vomiting, dizziness, or headache.

## Pharmacology
### Mechanism of action

Guaifenesin might act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi via stimulation of the gastric mucosa. This stimulation leads to an increased parasympathetic activity in the respiratory tract via the so-called gastro-pulmonary reflex, although some in vitro studies suggested that it might also act directly on the respiratory epithelium. This increase in volume and reduction in viscosity aids in the flow of respiratory tract secretions, allowing ciliary movement to carry the loosened secretions upward toward the pharynx. Thus, guaifenesin may increase the efficiency of the cough reflex and facilitate the removal of the secretions. Additionally, guaifenesin has a demonstrated central antitussive effect.

## History

Similar medicines derived from the guaiac tree were used as a generic remedy by American indigenous peoples when explorers reached North America in the 16th century. The Spanish encountered guaiacum wood "when they conquered Santo Domingo; it was soon brought back to Europe, where it acquired an immense reputation in the sixteenth century as a cure for syphilis and certain other diseases..."
The 1955 edition of the Textbook of Pharmacognosy states: "Guaiacum has a local stimulant action which is sometimes useful in sore throat. The resin is used in chronic gout and rheumatism, whilst the wood is an ingredient in the compound concentrated solution of sarsaparilla, which was formerly much used as an alternative in syphilis."
In the US, guaifenesin was first approved by the Food and Drug Administration (FDA) in 1952. Although previously deemed "Generally Regarded as Safe" in its original approval, the drug received a New Drug Application for the extended-release version, which received approval on 12 July 2002. Because of this, the FDA then issued letters to other manufacturers of timed-release guaifenesin to stop marketing their unapproved versions, leaving Adams Respiratory Therapeutics in control of the market. In 2007, Adams was acquired by Reckitt Benckiser. The drug is now sold over-the-counter by many companies, alone and in combination.

## Veterinary use

Guaifenesin's neurological properties first became known in the late 1940s. Guaifenesin is a centrally acting muscle relaxant used routinely in large-animal veterinary surgery. Guaifenesin is used in combination with, for example, ketamine, since guaifenesin does not provide analgesia or produce unconsciousness. In horses, the drug's biological half-life is 77 minutes. Premedication with xylazine (1.1 mg/kg) can reduce the dose required from 163 mg/kg (in geldings) to just 88 mg/kg.

## Society and culture
### Brand names

Guaifenesin is taken by mouth, and is supplied as a tablet, a capsule, an extended-release (long-acting) tablet, dissolving granules, and a syrup. It is available under many brand names, as either the sole active ingredient or part of a combination drug. Drugs combined with guaifenesin in over-the-counter preparations include the cough-suppressant dextromethorphan, analgesics such as paracetamol/acetaminophen, and decongestants such as ephedrine, pseudoephedrine, or phenylephrine.

### Economics

In 2014, sales of guaifenesin were estimated to be approximately $135 million per year in the United States.